PD57-7
ICGi052-B
General
Cell Line |
|
| hPSCreg name | ICGi052-B |
| Cite as: | ICGi052-B |
| Alternative name(s) |
PD57-7
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 9th July 2024 |
| User feedback | |
Provider |
|
| Generator | Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG) |
| Owner | Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG) |
| Distributors | |
| Derivation country | Russia |
External Databases |
|
| BioSamples | SAMEA115767763 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 45-49 |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Family history | All female relatives are affected. |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
Exome sequencing
NCBI SRR accession: SAMN42050731, BioProject PRJNA563295 Detailed analysis of the clinical exome sequencing data of the patient's PBMCs has revealed a mutation in the MAPT gene (c.2013T>G, rs63750756). |
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMN42050731 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | No |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Does consent expressly permit storage of genetic information? | Yes |
| Does consent prevent dissemination of genetic information? | No |
| How may genetic information associated with the cell line be accessed? | Open Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | Yes |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | Yes |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | Yes |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | FSBI Federal Neurosurgical Center |
| Approval number | protocol number 1, 14/03/2017 |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Addgene |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
| Source cell origin |
Blood drawn from a limb.
Synonyms
|
| Age of donor (at collection) | 45-49 |
| Collected in | 2021 |
| Source cell line vendor | FSBI Federal Neurosurgical Center |
| Passage number reprogrammed | 1 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Gelatin | ||||||||||||||||||
| Feeder cells |
Mouse embryonic fibroblasts Cellfinder Ont Id: EFO_0004040 |
||||||||||||||||||
| Passage method |
Enzymatically
TrypLE
|
||||||||||||||||||
| O2 Concentration | 20 % | ||||||||||||||||||
| CO2 Concentration | 5 % | ||||||||||||||||||
| Medium |
Other medium:
Base medium: KnockOut DMEM
Main protein source: Knock-out serum replacement Serum concentration: 15 % Supplements
|
||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|||||
| Alkaline Phosphatase |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| SSEA-4 |
Yes |
|||||
| SOX2 |
Yes |
|||||
| TRA 1-60 |
Yes |
Morphology pictures
Morphol PD57-7, 16p 20.tif
Morphology of ICGi052-B iPSC at passage 20
Differentiation Potency
In vitro spontaneous differentiation
Morphology
PD57-7 22p HNF3b_g+DAPI.tif
Immunofluorescent analysis for endoderm marker FOXA2/HNF3b (green signal) in ICGi052-B iPSC at passage 22. DAPI (blue signal)
Sp dif PD57-7 22p KRT18_r DAPI.tif
Immunofluorescent analysis for endoderm marker CK18 (red signal) in ICGi052-B iPSC at passage 22. DAPI (blue signal)
In vitro spontaneous differentiation
| Marker | Expressed |
| Actin, alpha 2, smooth muscle, aorta |
Yes |
| CD29 |
Yes |
Morphology
Sp dif PD57-7 22p aSMA_g DAPI.tif
Immunofluorescent analysis for mesoderm marker alfa SMA (green signal) in ICGi052-B iPSC at passage 22. DAPI (blue signal)
Sp dif PD57-7 22p CD29_r DAPI.tif
Immunofluorescent analysis for mesoderm marker CD29 (red signal) in ICGi052-B iPSC at passage 22. DAPI (blue signal)
In vitro spontaneous differentiation
Morphology
Sp dif PD57-7 22p bIII_r MAP2_g.tif
Immunofluorescent analysis for ectoderm markers TUBB3 (red signal) and MAP2 (green signal) in ICGi052-B iPSC at passage 22. DAPI (blue signal)
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
Karyotyping and G-banding show ICGi052-B iPSCs have a normal 46,XX karyotype at passage 20.
Passage number: 20
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.